Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment

Yu Wang,Hailan Wu,Junzhen Wu,Yaxin Fan,Xiaofen Liu,Yi Li,Jial Hu,Jing Zhang,Beining Guo
DOI: https://doi.org/10.1016/j.jchromb.2022.123129
2022-01-01
Abstract:Contezolid is a novel oxazolidinone antibiotic with good antibacterial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus. For the purpose to further characterize the pharmacoki-netics of contezolid and its major metabolite M2, accurate and rapid ultra-performance liquid chromatography-tandem mass spectrometric assays (UPLC-MS/MS) were developed and validated for simultaneous quantification of contezolid and M2 in human plasma and urine. The plasma samples were pretreated by liquid-liquid extraction. The automated solid phase extraction method was used to preprocess urine samples. ACQUITY UPLC (R) BEH C8 (2.1 mm x 100 mm, 1.7 mu m) column was used to separate the analytes with a gradient mobile phase of acetonitrile and water at a flow rate of 0.4 mL/min. The calibration curves showed good linearity over the concentration ranges of 0.0100-5.00 mu g/mL for contezolid in plasma and urine, 0.00200-1.00 mu g/mL in plasma and 0.0200-10.0 mu g/mL in urine for M2, respectively. For both plasma and urine assays, the intra-and inter-batch accuracy and precision were within 15% for all quality control levels, including the lower limit of quantitation. The methods were fully validated and successfully applied to a pharmacokinetic study of contezolid tablets in subjects with moderate hepatic impairment.
What problem does this paper attempt to address?